Kymera Therapeutics
KYMR
180 hedge funds and large institutions have $2.89B invested in Kymera Therapeutics in 2024 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 60 increasing their positions, 60 reducing their positions, and 28 closing their positions.
326% more call options, than puts
Call options by funds: $3M | Put options by funds: $704K
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
18% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 28
2.43% more ownership
Funds ownership: 108.3% → 110.73% (+2.4%)
2% more funds holding
Funds holding: 176 → 180 (+4)
0% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 60
12% less capital invested
Capital invested by funds: $3.27B → $2.89B (-$383M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$31.1M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$29.4M |
| 3 |
DM
Deerfield Management
New York
|
+$26.8M |
| 4 |
Janus Henderson Group
London,
|
+$16.4M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$28.4M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$13.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.6M |
| 4 |
Morgan Stanley
New York
|
-$11.2M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$10.9M |
KYMR Hedge Fund Activity: Q4 2024 in Review
180 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q4 2024, worth a combined $2.89B — down 12% from $3.27B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new KYMR positions and 28 closed out — a net gain of 5 holders — while 60 added to existing stakes and 60 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $31.1M. The largest seller was Deep Track Capital, exiting entirely with an estimated $28.4M sold.
- 180 institutional investors held Kymera Therapeutics (KYMR) as of Q4 2024, up from 176 in Q3 2024.
- Funds reported $2.89B of Kymera Therapeutics stock for Q4 2024, down 12% quarter-over-quarter.
- 33 funds opened new Kymera Therapeutics positions in Q4 2024 and 28 closed out, a net change of +5 holders.
- The largest Kymera Therapeutics buyer in Q4 2024 was Wellington Management Group, an estimated $31.1M added.
- The largest Kymera Therapeutics seller in Q4 2024 was Deep Track Capital, an estimated $28.4M sold.
Based on aggregated 13F filings for Q4 2024.